# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Truist Securities analyst Joon Lee maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maintains $150 price tar...
HC Wainwright & Co. analyst Douglas Tsao reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maintains $10...
Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into t...
Baird analyst Joel Beatty initiates coverage on Praxis Precision Medicine (NASDAQ:PRAX) with a Outperform rating and announc...
HC Wainwright & Co. analyst Douglas Tsao reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maintains $10...
Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into th...